Stock DNA
Pharmaceuticals & Biotechnology
CNY 5,890 Million (Mid Cap)
19.00
NA
2.04%
-0.52
14.78%
2.87
Revenue and Profits:
Net Sales:
289 Million
(Quarterly Results - Jun 2025)
Net Profit:
68 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.86%
0%
-2.86%
6 Months
3.11%
0%
3.11%
1 Year
-16.79%
0%
-16.79%
2 Years
-44.48%
0%
-44.48%
3 Years
-33.0%
0%
-33.0%
4 Years
-37.96%
0%
-37.96%
5 Years
-34.87%
0%
-34.87%
Shenzhen Lifotronic Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
17.42%
EBIT Growth (5y)
21.92%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.52
Sales to Capital Employed (avg)
0.51
Tax Ratio
4.81%
Dividend Payout Ratio
34.97%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
30.25%
ROE (avg)
15.82%
Valuation key factors
Factor
Value
P/E Ratio
19
Industry P/E
Price to Book Value
2.87
EV to EBIT
20.86
EV to EBITDA
17.71
EV to Capital Employed
4.87
EV to Sales
4.59
PEG Ratio
NA
Dividend Yield
2.04%
ROCE (Latest)
23.32%
ROE (Latest)
14.78%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
288.90
281.10
2.77%
Operating Profit (PBDIT) excl Other Income
48.50
57.10
-15.06%
Interest
0.20
1.60
-87.50%
Exceptional Items
0.00
0.00
Consolidate Net Profit
67.50
64.20
5.14%
Operating Profit Margin (Excl OI)
131.80%
173.20%
-4.14%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 2.77% vs 0.68% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 5.14% vs 38.96% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,133.60
1,132.30
0.11%
Operating Profit (PBDIT) excl Other Income
356.90
321.40
11.05%
Interest
7.50
4.10
82.93%
Exceptional Items
-13.80
-15.10
8.61%
Consolidate Net Profit
343.00
327.50
4.73%
Operating Profit Margin (Excl OI)
282.20%
258.00%
2.42%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 0.11% vs 16.30% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 4.73% vs 30.37% in Dec 2023
About Shenzhen Lifotronic Technology Co., Ltd. 
Shenzhen Lifotronic Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






